Researchers demonstrate how AI approaches can transform a vital layering technique for semiconductors.
Get the latest international news and world events from around the world.
“Engines Roared Like Exploding Suns”: Venus Aerospace Sparks Chaos as Rotating Detonation Rocket Test Ignites Groundbreaking US Leap Into the Future
IN A NUTSHELL 🚀 Venus Aerospace has tested a Rotating Detonation Rocket Engine, marking a milestone in propulsion technology. ⚡ The engine relies on supersonic explosions to generate thrust, offering higher efficiency than traditional methods. ✈️ The integration with the VDR2 ramjet could enable hypersonic vehicles to take off and land from conventional runways. 🌐
Neuroscientists Find That All Human Brains Are Connected through Extremely Low Frequency Electromagnetic Waves
For centuries, philosophers and scientists have speculated about the mysterious connections between human minds. Now, new research in neuroscience suggests that our brains may be linked in a very real, physical way — through extremely low frequency (ELF) electromagnetic waves.
Neuroscientists studying brain activity have found that the human brain not only generates its own electrical signals but also emits faint electromagnetic waves at extremely low frequencies. These ELF waves, which typically range from 1 to 30 Hertz, are so subtle that they were once thought to be biologically insignificant. However, recent experiments show that these signals can extend beyond the skull and interact with the electromagnetic environment around us.
What’s even more remarkable is that similar ELF patterns appear across different individuals, raising the possibility that brains can “tune in” to each other through this shared frequency spectrum.
FDA Approves Tonmya, First Fibromyalgia Medication in 15 Years
The US Food and Drug Administration (FDA) has approved Tonix Pharmaceuticals’ Tonmya (cyclobenzaprine HCl, formerly known as TNX-102 SL), a novel treatment form for fibromyalgia.1 The drug is now the first in a new category of non-opioid analgesics for fibromyalgia and the first new medication for this disorder in 15 years.
The FDA’s approval cited efficacy from 2 double-blind, randomized, placebo-controlled, phase 3 clinical trials of almost 1,000 patients that evaluated Tonmya as treatment for fibromyalgia. Across both phase 3 trials, Tonmya significantly reduced daily pain scores compared with placebo at the primary endpoint of 14 weeks. In these trials, a greater percentage of patients taking Tonmya experienced a clinically meaningful (≥30%) improvement in their pain after 3 months, as compared with placebo. Across phase 3 clinical trials with over 1,400 patients evaluated, Tonmya was generally well tolerated. The most common adverse events (incidence ≥2%) included oral hypoesthesia, oral discomfort, abnormal product taste, somnolence, oral paresthesia, oral pain, fatigue, dry mouth, and aphthous ulcer.
Psychiatric Times is the connection to Psychiatry and Mental Health, featuring clinical updates, expert views, and research news in multimedia formats.